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Background: Many aspects of the mechanisms involved in ultrasound-mediated therapy remain obscure. In
particular, the relative roles of drug and ultrasound, the effect of the time of ultrasound application, and the effect
of tissue heating are not yet clear. The current study was undertaken with the goal to clarify these aspects of the
ultrasound-mediated drug delivery mechanism.
Methods: Focused ultrasound-mediated drug delivery was performed under magnetic resonance imaging
guidance (MRgFUS) in a pancreatic ductal adenocarcinoma (PDA) model grown subcutaneously in nu/nu mice.
Paclitaxel (PTX) was used as a chemotherapeutic agent because it manifests high potency in the treatment of
gemcitabine-resistant PDA. Poly(ethylene oxide)-co-poly(D,L-lactide) block copolymer stabilized perfluoro-15-crown-
5-ether nanoemulsions were used as drug carriers. MRgFUS was applied at sub-ablative pressure levels in both
continuous wave and pulsed modes, and only a fraction of the tumor was treated.
Results: Positive treatment effects and even complete tumor resolution were achieved by treating the tumor with
MRgFUS after injection of nanodroplet encapsulated drug. The MRgFUS treatment enhanced the action of the drug
presumably through enhanced tumor perfusion and blood vessel and cell membrane permeability that increased
the drug supply to tumor cells. The effect of the pulsed MRgFUS treatment with PTX-loaded nanodroplets was
clearly smaller than that of continuous wave MRgFUS treatment, supposedly due to significantly lower temperature
increase as measured with MR thermometry and decreased extravasation. The time of the MRgFUS application after
drug injection also proved to be an important factor with the best results observed when ultrasound was applied
at least 6 h after the injection of drug-loaded nanodroplets. Some collateral damage was observed with particular
ultrasound protocols supposedly associated with enhanced inflammation.
Conclusion: This presented data suggest that there exists an optimal range of ultrasound application parameters
and drug injection time. Decreased tumor growth, or complete resolution, was achieved with continuous wave
ultrasound pressures below or equal to 3.1 MPa and drug injection times of at least 6 h prior to treatment.
Increased acoustic pressure or ultrasound application before or shortly after drug injection gave increased tumor
growth when compared to other protocols.
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Chemotherapy remains the treatment of choice for many
types of cancer. During the last decade, progress in
nanotechnology has enabled tumor-targeted delivery of
anticancer drugs, which simultaneously decreased side
effects and increased drug concentration in tumor tissue.
However, the dream of a ‘magic bullet’ that would exclu-
sively target the tumor remains elusive. In pursuit of this
goal, a number of groups have been directing their ef-
forts to increase the degree of drug tumor-targeting
using ultrasound-mediated drug delivery. In this ap-
proach, drug delivery with nanoparticles is combined
with tumor-directed ultrasound that affects both the
drug carrier and tumor tissue. The use of ultrasound
triggers drug release from the nanoparticle carrier and
increases drug and carrier extravasation and deposition
in tumor cells.
Focused ultrasound (FUS) has a number of advantages
when compared with other physical methods used in
tumor therapy: it can penetrate deep into the body, can
be focused in a region with a diameter of approximately
1 mm, can be carefully controlled, and is completely
non-invasive. FUS has both thermal (local heating of tis-
sue to hyperthermia or ablative temperatures) and non-
thermal mechanisms (i.e., cavitation and radiation force).
These mechanisms are expected to work synergistically
to trigger drug release from the carrier, increase extrava-
sation and internalization of carrier and drug, and in-
crease drug diffusion in tumor tissue, which ultimately
results in an enhanced treatment outcome.
Development of real-time imaging methods such as
magnetic resonance imaging (MRI) or ultrasound imaging
allows precise spatiotemporal control of FUS-mediated
drug delivery. Imaging assists in the identification of the
target, guidance of ultrasound action, and evaluation of
therapeutic efficacy. Moreover, real-time temperature
measurements during treatment using MRI thermometry
provide data that can be used in a feedback controller to
enable greater control of the energy delivery [1,2].
Bioeffects of ultrasound in drug delivery may be en-
hanced by the application of microbubbles, which have
been widely used as ultrasound contrast agents. This
novel application of microbubbles is associated with en-
hanced cavitation [3-13]; microbubbles have been suc-
cessfully used for opening blood/brain and blood/retinal
barriers [7,9,14,15] or enhancing thrombus dissolution
[16-18]. However, the size of microbubbles (usually 2 to
10 microns) precludes their extravasation into the tumor
tissue.
We have developed drug-loaded perfluorocarbon
nanoemulsions that serve as nanoscale microbubble pre-
cursors [19-24]. Due to their size (200 to 300 nm, i.e., at
least the order of magnitude is smaller than microbubbles),
nanodroplets can extravasate into the tumor tissue. Underthe action of tumor-directed ultrasound, perfluorocarbon
droplets convert into microbubbles [25-28]. Droplet-to-
bubble conversion results in a release of an encapsulated
drug [21,23,29-33]. Using paclitaxel-loaded perfluoro-
carbon nanoemulsions, successful therapy of breast, ovar-
ian, and pancreatic cancer has been achieved in preclinical
studies using animal models; in these studies, unfocused
ultrasound was blindly applied to the tumor region [21,22].
Despite these successes, many aspects of the mecha-
nisms involved in ultrasound-mediated therapy remain
obscure. In particular, the relative roles of drug and
ultrasound applications, the effect of the time of ultra-
sound application, and the effect of tissue heating are
not yet clear. The current study was undertaken with
the goal to clarify these aspects of the FUS-mediated
drug delivery mechanism. A pancreatic ductal adeno-
carcinoma (PDA) model grown subcutaneously in nu/nu
mice was used as a tumor model.
PDA is the fourth leading cause of death from can-
cer in the USA, and novel approaches to PDA therapy
are urgently needed. Poor PDA response to conven-
tional chemotherapy is at least partly accounted for by
poor tumor vascularization and high content of
stroma that precludes effective drug delivery and diffu-
sion throughout tumor volume [34-44]. Since FUS-
mediated drug delivery enhances drug extravasation
and diffusion, this treatment modality is expected to
have significant impact on the development of effect-
ive PDA therapy.
In this study, FUS-mediated drug delivery was performed
under MRI guidance. Paclitaxel (PTX) was used as a che-
motherapeutic agent because it manifested high potency in
the treatment of gemcitabine-resistant PDA [45]. Poly
(ethylene oxide)-co-poly(D,L-lactide) (PEG-PDLA) block
copolymer stabilized perfluoro-15-crown-5-ether (PFCE)
nanoemulsions or their mixtures with polymeric micelles
were used as drug carriers [21,31,33]. As manifested by the
appearance of harmonic frequencies in the fast Fourier
transform emission spectra, PFCE nanodroplets were
converted into microbubbles under ultrasound irradiation
and underwent stable cavitation in both liquid emulsions
and gel matrices [32]. Droplet-to-bubble conversion pro-
ceeded presumably via the evolution of dissolved oxygen
into a separate phase [21].
The objective of this study is to better understand the
advantages and limitations of the FUS-mediated drug
delivery application to PDA therapy.
Materials and methods
Drug
PTX was used as a chemotherapeutic agent because it
has manifested high potency in the treatment of
gemcitabine-resistant PDA [45]. PTX was obtained from
LC Laboratories (Woburn, MA, USA).
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PTX-loaded perfluorocarbon nanodroplets were manufactured
from PTX-loaded micelles formed by the water-soluble,
biodegradable block copolymer PEG-PDLA with a mo-
lecular weight of either block of 2,000 Da (Akina, Inc.,
West Lafayette, IN, USA). PTX-containing PEG-PLA mi-
cellar solutions were prepared by a solid dispersion tech-
nique [20]. Typically, 20 or 50 mg PEG-PDLA and 5 mg
PTX were co-dissolved in 1 ml tetrahydrofuran (THF).
The THF was then evaporated under gentle nitrogen
stream at 60°C or pumped out at room temperature.
PTX-loaded micelles were reconstituted by dissolving re-
sidual gel matrix in 1 ml phosphate buffered saline (PBS;
pH 7.4). Then 10 μl PFCE (MW 580.01, Oakwoods Prod-
ucts, Inc., West Columbia, SC, USA) was introduced into
micellar solution and emulsified by sonication on ice
(VCX500, Sonics and Materials, Inc., CT, USA) to obtain
paclitaxel-loaded droplets of the composition 2% or 5%
PEG-PDLA/0.5% PTX/1% PFCE. The components of mi-
cellar or nanodroplet formulations were obtained from
commercial sources and used without further purification.
Micellar solutions and perfluorocarbon compounds were
sterilized by filtration and mixed in a sterile test tube be-
fore being sonicated on ice for the generation of the
nanoemulsion. The size of PFCE nanodroplets (both
empty and drug loaded) was in the range 250 to 300 nm
(Figure 1).
Subcutaneous PDA MiaPaCa-2 tumor model
Human pancreatic cancer MiaPaCa-2 cells were obtained
from the American Type Culture Collection (Rockville,
MD, USA) and transfected with red fluorescence protein
(RFP) [47]. Because only live cells generate RFP and
therefore are fluorescent, the intravital whole mouseFigure 1 A nanoparticle size distribution for 5% PEG-PDLA/1%
PFCE formulation. Fifty-nanometer particles are residual micelles;
two-hundred sixty-two-nanometer particles are nanodroplets.
Nanodroplet size may be decreased by increasing sonication
pressure during emulsification. Micelle fraction can be decreased by
decreasing copolymer concentration and/or increasing PFCE
concentration [46]. PTX loading slightly increases nanodroplet sizes
(e.g., from 260 to 280 nm).fluorescence imaging allowed the monitoring of tumor
size and death of clusters of tumor cells. The excitation
and emission peaks for the RFP were 563 and 587 nm,
respectively.
Cells were maintained in Dulbecco's modified Eagle
medium (DMEM) supplemented with 10% heat-inactivated
fetal bovine serum (Gibco, Grand Island, NY, USA) at 37°C
in a 5% CO2 incubator. Male nude mice between 6 to 8
weeks of age were utilized (NCr-Nu/Nu, National Cancer
Institute, Frederick, MD, USA). For the tumor induction,
mice were anesthetized with isoflurane and received a sin-
gle subcutaneous injection of 1.5 × 106 MiaPaCa-2 cells
suspended in 150 μL of serum-free DMEM. Tumors were
grown in either the shoulder or thigh region and allowed to
progress until reaching an initial size of at least 175 mm3,
at which point mice were randomly assigned to a treatment
group. Since the tumor size of untreated animals roughly
doubles every week, the target initial tumor size of 175
mm3 was often exceeded, and in the majority of animals,
the initial tumor size was 200 to 300 mm3 immediately be-
fore treatment. To assess the effect of the initial tumor size
on treatment outcome, tumors were allowed to grow to the
volume of roughly 1,000 mm3 in a small subset of animals.
All experiments were approved by the University of Utah
Institutional Animal Care and Use Committee.
MRgFUS treatments
At an assigned time point (2 or 8 h) before magnetic
resonance-guided FUS (MRgFUS) therapy, mice were
systemically injected through the tail vein with either
empty (i.e., non-PTX-loaded) or PTX-loaded PFCE
nanodroplets (PTX dose 40 mg/kg). In one experiment,
the MRgFUS treatment was performed 10 min before
drug injection.
The MRgFUS treatments were executed with a small
animal MRgFUS system (Image Guided Therapy, Inc.,
Pessac, France) with a 16-element annular transducer (f =
3 MHz, rc = 3.5 cm, FWHM = 1 × 3 mm) that could be
translated in plane with piezo-ceramic motors. The system
was placed in a Siemens 3 T Trio scanner, and
temperature imaging was obtained using a 2D-segmented
echo-planar imaging (EPI) sequence (TR/TE = 60/10 ms,
FA = 15°, EPI = 3, fat saturation, 752 Hz/pixel, 1.4 s acqui-
sition, 2 × 2 × 3 mm3 resolution, single slice). Tempera-
tures were reconstructed using a referenceless algorithm
[48] and were post-processed with zero-filled interpolation
to yield 1 × 1 × 3 mm3 voxel spacing [49].
Four different acoustic peak pressure levels were ap-
plied: 2.4, 3.4, 4.2, and 4.8 MPa. These levels were calcu-
lated in water at the site of sonication assuming that the
beam intensity is distributed evenly over the focal spot.
Most experiments in the PTX-nanodroplet + MRgFUS
group were performed with continuous wave (CW)
ultrasound (N = 24); in parallel with CW experiments,
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sound (N = 4), with pressure levels matching those of
CW counterparts.
Treatments were conducted using the following proto-
col: the free-breathing anesthetized mouse (ketamine100
mg/kg, xylazine 20 mg/kg) was placed on the agar
holder such that the tumor protruded through the hole
as shown schematically in Figure 2A. In order to ensure
an adequate acoustic window, the animal was always po-
sitioned with the tumor directly above the ultrasound
transducer. An axial image of a mouse on the MRgFUS
device placed in the magnet is shown in Figure 2B. The
transducer and agar holder are shown. The mouse is
flanked by warm-water-filled tubes to help regulate its
body temperature during the treatment.
The tumor was localized with high-resolution sagittal
and axial images. Temperatures were monitored in a
single coronal slice placed at the focal plane of the trans-
ducer. Three beam path patterns, two spiral patterns
and one grid pattern, were used in these experiments
(Figure 3). Transducer speed was 1 and 2.5 mm/s in the
5-mm- and 8-mm-diameter spiral patterns, respectively,
and 0.1 mm/s in the grid pattern.
Monitoring treatment outcome
Time lines of tumor growth or regression were docu-
mented using three complimentary monitoring tech-
niques: tumor size measurements with a caliper,
tumor fluorescence imaging, and photography. All
three techniques produced similar results. Fluores-
cence imaging allowed the monitoring of both tumor
growth/regression and cell death in the tumor tissue
(see below).
Tumor volume was calculated using the following
equation:
V ¼ LW 2 =2 ð1Þ
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Figure 2 Schematic representation and axial image of mouse on sma
positioning on the small animal MRgFUS device; (B) An axial image of mou
and agar holder. The white arrow indicates the tumor (initial size 455 mm3The end point corresponded to the tumor, reaching
about 2 cm in diameter; the time to reach this point was
taken as a life span.
Animal groups
The treatment groups and number of animals used in the
study are listed in Table 1. Experimental parameters in-
cluded PTX-loaded nanodroplets vs. empty nanodroplets,
applied MRgFUS pressure, and time of ultrasound
application.
Statistical treatment
The statistical significance of the differences between
the pairs of groups were calculated using the two-tailed,
two-sample equal variance t test; the differences were
considered statistically significant for p < 0.05.
Results
Effect of the combined treatment with PTX-loaded
nanodroplets and MRgFUS on tumor growth/regression
and mouse life span
Two different scenarios of the tumor response to treatment
were observed: the first involved a complete tumor reso-
lution without recurrence. This was observed in four mice
after a single treatment with PTX-loaded nanodroplets and
CW MRgFUS at an acoustic peak pressure of 2.4 or 3.4
MPa for either a spiral or grid beam trajectory. An example
of a complete tumor resolution with both photograph and
fluorescence images is presented in Figure 4.
The spiral steering patterns were executed with a much
faster velocity than that of the grid pattern. This faster vel-
ocity in conjunction with the short MR acquisition time
(approximately 1 s) led to unreliable temperature measure-
ments from phase changes throughout the image caused
by transducer motion. Grid steering patterns provided
more robust temperature imaging during the treatment.
An example of the temperature rise obtained with a grid
steering pattern is presented in Figure 5. The tumor was
treated with PTX-loaded nanodroplets and CW MRgFUS
delivered for 350 s at 3.4 MPa. Panel (A) shows the axial




ll-animal MRgFUS device. (A) Schematic representation of the mouse
se 59 on the small animal MRgFUS device with labeled transducer
).
Figure 3 Spiral and grid ultrasound beam patterns used in the study. Transducer speed was 1 and 2.5 mm/s in the (A) 5-mm- and
(B) 8-mm-diameter spiral patterns, respectively, and 0.1 mm/s in the (C) grid pattern.
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shows a coronal image through the tumor and the re-
gion of interest for the maximum temperature projec-
tion is shown in panel (C), in which the trajectory
boundaries are indicated by the overlayed rectangle. TheTable 1 Treatment parameters for all animals used in the stu
N Treatment group MRgHIFU
Trajectory Acoustic
pressure (MPa)
7 Negative control (no injection,
no MRgFUS)
N/A N/A
7 PTX-nanodroplets + No
MRgFUS




3 Empty nanodroplets + No
MRgFUS
N/A N/A

















aMean values plus/minus standard deviations are presented; bMice that died within
higher than 4.2 MPa) were excluded from the life span calculation; cSurvivors (N = 2trajectory path is shown in panel (D) with voxel locations
for the temperature response as a function of time plotted
in panel (E). The mean temperature change (including all
voxels that achieved a temperature rise of >5°C) in the
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7.0 ± 0.8




N/A N/A 6 to 8 3.5 ± 0.5




100 300 1 to 2 7.0 ± 1.0
100 153 ± 54 6 to 8 10.3 ± 1.6c






50 (50 ms) 300 6.0 ± 1.4
50 (50 ms) 300
50 (100 ms) 300
50 (50 ms) 300
several days after the treatment (observed for the MRgFUS pressure of or
for the grid trajectory) were excluded from the life span calculation.
Figure 4 Mouse photographs and whole-body fluorescence images before and after combined PTX-loaded nanodroplet and MRgFUS
treatment. Photographs (A, C) and whole-body fluorescence images (B, D) of a mouse before (A, B) and after (C, D) combined treatment with
PTX-loaded nanodroplets and MRgFUS. The dashed circles in (B,D) indicate the tumor location. Treatment parameters: MRgFUS was applied 8 h
after drug injection; spiral beam pattern (5-mm diameter) shown in Figure 3A; FUS at 3.1 MPa; sonication time of 3 min. The tumor did not recur
during a 5-month observation. The former location of the tumor is still slightly visible in D, indicated by the dashed white circle.
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3); after the
treatment, the tumor regressed quickly and there was no
tumor visible to eye or by RFP imaging. However, tumor
regrowth started 6 weeks after the treatment. The recur-
rent tumor responded to a second treatment (nine injec-
tions of PTX-loaded nanodroplets without MRgFUS,
twice a week for 4.5 weeks) indicating that tumor cells
did not develop drug resistance. Histological examin-
ation of a tumor control showed the presence of mitotic
cells and a pronounced stroma. In a recurred tumor in a
mouse that received the combined treatment of PTX-
nanodroplets and MRgFUS, no evidence of stroma andD
A B
E
Figure 5 Images of mouse, maximum temperature projection in time
curve. (A) Axial image of a mouse on the MRgHIFU device. The transducer
with region of interest defined. (C) Maximum temperature projection in tim
trajectory boundaries. (D) MRgFUS trajectory with plotted voxel locations in
response as a function of time for voxels indicated in (D). (F) Time curve o
Total MRgFUS time was 350 s at a pressure of 3.4 MPa.substantial necrosis in the residual tumor areas was ob-
served. The presence of significant hemosiderin deposi-
tions in a treated tumor is a sign of the infarction of the
initially treated tumor that appeared completely resolved
and replaced with the scar tissue. For a different mouse
with a larger initial tumor (V0 = 264 mm
3) treated with
the same protocol, complete tumor resolution took a
longer time (8 weeks). The tumor did not recur during a
5-month observation.
The cases of complete resolution of pancreatic cancer
occurred after a single pancreatic tumor treatment with
PTX-loaded nanodroplets and MRgFUS. This was observedC
F
, MRgFUS trajectory, temperature response for voxels, and time
and agar holder are shown. (B) Coronal image through the tumor
e within region of interest. White rectangle indicates the grid
dicated. One-millimeter spacing between all points. (E) Temperature
f the mean temperature rise in the treatment plane for all voxels >5°C.
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droplets with various MRgFUS parameters. Survivors were
observed at ultrasound acoustic pressures of 2.4 (N = 1) or
3.4 MPa (N = 3) and did not depend on the beam steering
pattern (i.e., spiral or grid).
A different tumor response scenario to the combined
PTX-loaded nanodroplet and MRgFUS treatment is il-
lustrated in Figure 6 for a mouse treated with the grid
pattern at 2.4 MPa. The upper panel shows a mouse
photograph and fluorescent image taken 1 h before the
treatment; the lower photograph and image were taken
3 weeks later. This image suggests that tumor cells were
killed in the MRgFUS-treated area but remained viable
around the treated volume causing a gradual tumor
growth around the treated area. The growth rate of this
tumor was close to that of tumors not treated with
MRgFUS. Temperature data for the animal shown in
Figure 6 is displayed in Figure 7; a very marginal
temperature response to MRgFUS therapy was observed.
It is important to underline that the therapeutic effect
of PTX-loaded nanodroplets was also observed without
the MRgFUS treatment (Figure 8); however, complete
tumor resolution has never been achieved after a single
nanodroplet injection without MRgFUS, and the average
mouse life span after a single treatment with PTX-
loaded nanodroplets without ultrasound (7 ± 0.8 weeks,
N = 7) was shorter than that of mice treated with
MRgFUS (10.3 ± 1.6 weeks, N = 19, grid + spiral trajec-
tory, survivors were excluded from the calculation,A B
C D
Figure 6 Mouse photographs and whole-body fluorescence images b
treatment. Mouse photographs (A, C) and whole-body fluorescence imag
PTX-loaded nanodroplets and MRgFUS therapy; ultrasound was applied 8 h
location is indicated by a dashed circle in all images.Table 1); the difference between these two groups was
statistically significant (p < 0.05).
The role of drug in the MRgFUS-mediated tumor
treatment: comparison of the effects of empty and
drug-loaded nanodroplets
Dramatic differences were observed in the tumor re-
sponses to MRgFUS treatment with and without drug.
The MRgFUS tumor treatment without any injection did
not affect tumor growth or mouse life span; any differ-
ences with control were not statistically significant.
Injections of empty (i.e., not PTX-loaded) nanodroplets
without MRgFUS application or with MRgFUS pressure
levels below 4.2 MPa did not exert any effect on the tumor
growth rates or average mouse life span. Six mice were
treated with empty nanodroplets of various MRgFUS pres-
sure levels from 2.4 to 4.2 MPa; their average life span was
3.5 weeks, similar to the negative control; however, all mice
treated with a pressure of 4.2 MPa died within 1 to 3 weeks
after the treatment. In two cases, tumor growth was notice-
ably accelerated (data not shown). In contrast, the average
life span of mice treated with PTX-loaded nanodroplets
and MRgFUS was threefold longer (10.3 weeks). These data
indicate that for the combined PTX-loaded nanodroplets/
MRgFUS treatment, the main therapeutic effect was caused
by the drug and not by the ultrasound. Still, as follows from
Figure 8 and Table 1, MRgFUS did significantly enhance
the action of the drug for certain combinations of ultra-
sound parameters.efore and after combined PTX-loaded nanodroplet and MRgFUS
es (B, D) taken before (A, B) and 3 weeks after treatment (C,D) with
after drug injection at 2.4 MPa with a grid trajectory. The tumor
Figure 9 Effect of ultrasound pressure on the tumor growth
curves in the presence of PTX-loaded nanodroplets. No MRgFUS
(N = 7, diamonds); MRgFUS at 4.2 MPa (N = 3, triangles); MRgFUS at
4.8 MPa (N = 2, squares).
Figure 7 Temperature response for the mouse shown in Figure 6.
The temperature rise for three individual voxels indicated in the
treatment path is shown.
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For mice treated with PTX-loaded nanodroplets and
MRgFUS, increasing ultrasound pressure above 4.2 MPa
exerted a detrimental effect on the tumor growth and
animal survival (Figure 9); moreover, at a pressure level
of 4.2 MPa and especially at 4.8 MPa, grid-shaped skin
burns that required special treatment were observed.
The burns were resolved within 2 to 3 weeks.
Effect of the time of ultrasound application
Experiments were performed with ultrasound application
either 2 (N = 5) or 6 to 8 h after the injection (N = 23). In
one experiment, ultrasound was applied 10 min before the
injection of PTX-loaded nanodroplets. No effect of
MRgFUS was observed when ultrasound was applied ei-

























time after treatment, days
Control N=3
PTX droplets no 
FUS N=7
PTX droplets + 
FUS, best results 
N=4
Figure 8 Tumor growth curves. Control (N = 3, squares); Tumors
treated with PTX-loaded nanodroplets without ultrasound (N = 7,
triangles); Best results for tumors treated with PTX-loaded
nanodroplets and MRgFUS (N = 4, diamonds).growth rates and average life span did not differ from
those observed for PTX-loaded nanodroplets without
MRgFUS.
Effect of pulsed ultrasound
The experiments for pulsed and CW parameters were
performed in parallel. The average life span of mice
treated with pulsed ultrasound with various FUS param-
eters (6 ± 1.4 weeks, N = 4) was significantly lower than
that of mice treated with CW ultrasound (10.3 ± 1.6
weeks, N = 19).
Effect of the initial tumor size
The effect of the therapy depended strongly on the ini-
tial tumor size at the start of treatment. When the initial
tumor size exceeded 1,000 mm3, the combined treat-
ment by PTX-loaded nanodroplets and MRgFUS could
not completely stop tumor growth; after the initial de-
crease of the tumor size, tumor growth resumed in 3 to
4 weeks. The average life span of animals with large ini-
tial tumors was increased by the treatment (roughly
from 3 weeks for controls to 6 to 8 weeks for treated
animals), but all tumors continued to grow despite
the treatment. Increasing the MRgFUS-treated vol-
ume by the treatment of the two tumor planes rather
than one plane did not exert any positive effect on
the life span of animals with large initial tumors.
Moreover, tumor growth was accelerated after the
two-plane treatment, presumably due to the increased
heating (see Discussion).
Safety issues and collateral damage
Seven of the total of fifty-one animals (14%) treated with
MRgFUS died within several days of the MRgFUS treat-
ment. Four of seven animals died after the treatment
with empty nanodroplets and MRgFUS at pressure levels
of 4.2 or 4.8 MPa; two animals died after the treatment
with the same MRgFUS parameters without any injec-
tion. One animal died two days after the combined
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at 4.2 MPa. No animal deaths resulted from the
nanodroplet treatment without MRgFUS indicating that
animal deaths were related to the MRgFUS treatment.
Presence of empty nanodroplets during MRgFUS treat-
ment appeared to increase the death rate. Although the
exact mechanism that led to the animal's death is un-
known, it is suspected that it may be due to peritonitis.
A post-treatment analysis of MR images of coronal slices
of MRgFUS treated animals suggested that the collateral
damage occurred when gas-filled intestines were located
in the far field of the ultrasound beam (Figure 10).
Discussion
Ultrasound may exert both positive and negative effects
on biological tissue. Positive effects may be related to in-
creased drug carrier and drug extravasation, drug release
from carrier, and drug internalization by tumor cells. On
the other hand, vasodilation or vasoconstriction in re-
sponse to ultrasound and cavitating microbubbles may
result in the cellular response of surrounding tissues
such as inflammation, edema, hemorrhage, which could
be negative. Tissue response to ultrasound-induced
heating is multifaceted as well. In the absence of the
drug, the response to sub-ablative heating may be nega-
tive due to enhanced perfusion that promotes tumor
growth. In contrast, in the presence of the drug, en-
hanced perfusion is a positive factor that promotes drug
delivery to tumor tissue; in addition, hyperthermiaFigure 10 MRI showing gas-filled intestines in the ultrasound
far-field. This image is representative for seven mice that died
within several days after MRgFUS treatment. The transducer and
agar holder are labeled. The long and short arrows identify the
tumor and intestines, respectively.increases vascular wall and plasma membrane perme-
ability thus increasing drug internalization by tumor
cells. The ultimate biological response to ultrasound pre-
sumably depends on the prevalence of positive or nega-
tive factors which is expected to depend on the
treatment protocol as well as biological factors.
In our experiments, MRgFUS was applied at sub-
ablative pressure levels and only a fraction of the
tumor was treated. For tumor therapy, this situation is
unfavorable. Ultrasound treatment caused hyperther-
mia (Figure 5) but did not induce coagulative necrosis
of tumor tissue as manifested by the preservation of
the tumor cell fluorescence after the MRgFUS treat-
ment without the drug. At ultrasound pressure levels
used in this study, MRgFUS treatment without any in-
jection did not exert statistically significant effects on
the tumor growth or animal life span. In the presence
of empty nanodroplets, the effect of MRgFUS appeared
to be negative, especially at higher pressure levels (in-
creased tumor growth, early animal death), which
could be related to the droplet-to-bubble transition
and bubble cavitation that induced tissue inflamma-
tion. In the presence of the drug, these negative effects
of the ultrasound treatment were suppressed. More-
over, the MRgFUS treatment enhanced the action of
the drug (Figure 8 and Table 1). This may be associ-
ated with the enhanced tumor perfusion and cell per-
meability caused by mild hyperthermia, which in the
presence of the drug are positive factors that increase
drug supply to tumor cells.
However, increasing ultrasound pressure above a cer-
tain threshold (4.2 MPa) decreased the positive effect of
the combined PTX-loaded nanodroplet/MRgFUS treat-
ment (Figure 9). This shows that positive effects of the
ultrasound treatment in the presence of nanodroplets
compete with negative effects in this animal model; ad-
verse effects causing tissue inflammation are enhanced
at higher ultrasound pressure levels. Even in the pres-
ence of the drug, one animal died within a couple of
days after the MRgFUS treatment at 4.2 MPa. However,
the death rate caused by the MRgFUS treatment was
much higher with empty droplets.
It is not immediately clear if the chemotherapeutic
drug may suppress the inflammation. One hypothesis
was suggested by Dr. Klibanov who proposed that the
nanodroplet-encapsulated PTX could kill harmful mac-
rophages that cause tissue inflammation (personal com-
munication). This supposition remains to be explored.
As suggested by the post-treatment analysis of MR im-
ages, ultrasound-induced collateral damage could result
from ultrasound reflection from the air-filled structures
(Figure 10); possible intra-intestinal gas bubble cavita-
tion in the ultrasound far field could be a peritoneum-
damaging factor that results in the animal death.
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served between the mean temperature in the treated
plane and the treatment outcome. More data are needed
to draw a conclusion on the relative roles of thermal and
mechanical modes of ultrasound action in the combined
treatment with PTX-loaded nanodroplets and MRgFUS.
The effect of the pulsed MRgFUS treatment with
PTX-loaded nanodroplets was clearly smaller than that
of CW MRgFUS treatment, which may be related to sig-
nificantly lower temperature increase and/or decreased
extravasation [50].
The time of the MRgFUS application proved to be an
important factor. The positive effect of the MRgFUS
treatment in the presence of PTX-loaded nanodroplets
was observed when MRgFUS therapy was performed 6
to 8 h after the injection of drug-loaded nanodroplets
but was aborted when MRgFUS was applied before or
shortly after the drug injection. This underlines the role
of the nanodroplet accumulation in the tumor volume
for the success of the treatment. The data suggest that at
the conditions studied, MRgFUS treatment did not no-
ticeably enhance nanodroplet extravasation into the
tumor tissue. The opposite was observed in a recent
study where excised carotid arteries were inserted in
PBS [50]. It appears reasonable to suggest that the ultra-
sound susceptibility of blood vessels inserted in solid
matrices could differ from that of vessels inserted in li-
quid. It might well be that enhanced extravasation
in vivo requires higher ultrasound pressures than those
used in this work. At this time, we do not have enough
data to further explore this issue. The data presented
also show that nanodroplet accumulation in the tumor
is desirable before the ultrasound application. The tumor
accumulation of nanodroplets may take hours [21,22].
The presence of nanodroplets in blood vessels of the
normal tissue in the path of the beam may scatter ultra-
sound; it may also cause collateral damage induced by
the microbubble cavitation in the ultrasound far field.
Since increasing the sonicated volume did not result in
a better treatment outcome for large tumors, the inability
to completely suppress tumor growth was most probably
related to the insufficient concentration of drug in the
tumor rather than the small sonicated tumor fraction.
The data presented above suggest that there exists an
optimal range of the time of ultrasound application and
ultrasound pressure levels below which the treatment does
not exert any effect and above which the effect of the
treatment is decreased. It should be emphasized that posi-
tive treatment effects and even complete tumor resolution
were achieved with only a single treatment of just a frac-
tion of the pancreatic tumor. This shows the potential of
using the combined tumor treatment with PTX-loaded
nanodroplets and MRgFUS for the therapy of the pancre-
atic cancer, one of the most lethal cancer types.Competing interests
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